Celldex Therapeutics (CLDX) Stock: Buy, Sell, or Hold?
CLDX - Celldex Therapeutics, Inc
$29.30
-1.13 (-3.71%)
▼
5d:
-8.95%
30d:
-24.45%
90d:
-25.08%
WAIT
LOW Confidence
Analysis Updated: Oct 8, 2026 12:00 AM ET
Earnings: Nov 09, 2026
30d
Get Alerted When CLDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CLDX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CLDX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CLDX is currently trading at $29.30, which is considered oversold relative to its 30-day fair value range of $31.70 to $39.14.
Technical Outlook: Technically, CLDX is in a uptrend. The price is currently testing key support at $28.63. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: CLDX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $63.07 (+115.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLDX is in a uptrend. The price is currently testing key support at $28.63. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: CLDX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $63.07 (+115.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$31.70 -
$39.14
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 115.3% below Wall St target ($63.07)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$31.70 -
$39.14
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$28.63
Resistance Level
$32.88
Current Trend
Uptrend
Technical data as of
Oct 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.92
Wall Street Target
$63.07
(+115.3%)
Revenue Growth (YoY)
-97.0%
Share & Embed Analysis
Last updated: October 09, 2026 3:40 AM ET
Data refreshes hourly during market hours. Next update: 4:40 AM
Data refreshes hourly during market hours. Next update: 4:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
27 analysts |
$92 | 44 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$285 | 40 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 69 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 49 HOLD |
